![Douglas Flora: Excited to participate in the Cancer Care Business Exchange in Boston](https://oncodaily.com/pub/uploads/2024/06/Untitled-2-e1723566202325.png)
Douglas Flora: Excited to participate in the Cancer Care Business Exchange in Boston
Douglas Flora shared on LinkedIn:
“Just 2 weeks to go until the Clinical Pathways Congress and Cancer Care Business Exchange in Boston!
The event brings together industry leaders, healthcare professionals, researchers, payment reform experts, and innovators to discuss and showcase transformative oncology delivery, payment, and business models.
I am excited to participate in this panel with James Hamrick, Jeff Hunnicutt, and Will Shapiro. These are important topics, and these guys know their stuff. By exploring innovative strategies and solutions, we aim to transform the current cancer care landscape, ensuring better access, higher quality care, and improved patient outcomes.
Together, we will delve into complex topics such as the role of AI in oncology, the significance of and barriers to effective clinical trial recruitment in the community setting, the power and impact of vertical integration, trends in practice consolidation, the EOM outlook from diverging perspectives, and so much more.
We invite you to refine your approach in Boston on September 6–8, 2024.
Use code VIP to save 15% on registration.”
Source: Douglas Flora/LinkedIn
Douglas Flora is the Executive Medical Director of Oncology Services at St. Elizabeth Healthcare, overseeing clinical operations, strategic planning, and the expansion of cancer programs. He is also the co-founder of the Center for Precision Medicine; Genomic Health.
As the Editor-in-Chief of ‘AI in Precision Oncology,’ the first peer-reviewed academic journal dedicated to this field, he plays a pivotal role in advancing research. He is also an active board member of the American Cancer Society and ACCC, where he contributes to advocacy, education, and innovation within the cancer community.